Sep 29, 2025
Human iPSCs
- Maria Jose Perez J.1
- 1Institut Imagine
- Team Deleidi
Protocol Citation: Maria Jose Perez J. 2025. Human iPSCs. protocols.io https://dx.doi.org/10.17504/protocols.io.rm7vz9o3xgx1/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: September 25, 2025
Last Modified: September 29, 2025
Protocol Integer ID: 228174
Funders Acknowledgements:
ASAP
Abstract
Human iPSCs
Troubleshooting
Human iPSC lines were derived from patients who signed an informed consent form, with study approval granted by the Ethics Committee of the Medical Faculty and University Hospital Tübingen (Ethikkommission der Medizinischen Fakultät am Universitätsklinikum Tübingen).
Three healthy control iPSC lines were used:
a) Two previously generated and characterized healthy donor-derived lines (C1 and C2) (Ref. main text 8, 84, 85).
b) One commercial control line (C3; Kolf2.1J, RRID:CVCL_B5P3; Jackson Laboratory, Bar Harbor, USA).
PITRM1-knockout iPSC lines were previously generated from C2(Ref. main text 8) and were used in this study.
All iPSC lines were routinely tested for mycoplasma contamination using Venor‱GeM Classic (Minerva Biolabs Inc., Berlin, Germany).
The iPSC lines were maintained in mTeSR‱ Plus stabilized feeder-free maintenance medium (STEMCELL Technologies, Vancouver, BC, Canada).
For each experiment, the specific iPSC lines used and the number of independent differentiations were indicated in the figure legends.